1052114-80-3

Basic information

• Product Name: ethyl 5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxylate
• Synonyms: ethyl 5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxylate;ethyl 5-(4-fluorophenyl)-1,4-dihydro-4-oxopyridine-3-carboxylate
• CAS NO: 1052114-80-3
• Molecular Weight: 261.253
• Mol File: 1052114-80-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: ethyl 5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxylate(1052114-80-3)
• EPA Substance Registry System: ethyl 5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxylate(1052114-80-3)

Safety Data

• Hazardous Substances Data: 1052114-80-3(Hazardous Substances Data)

Upstream product

• 405-50-5 p-Fluorophenylacetic acid 
• 1035695-10-3 5-[2-(4-fluorophenyl)-1-hydroxyethylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 459-04-1 4-Fluorophenylacetyl chloride 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 221121-37-5 4-(4-fluorophenyl)-3-oxobutanoic acid ethyl ester 
• 290-87-9 1,3,5-Triazine 

Downstream Products

• 1052114-81-4 5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridin-3-ylcarboxylic acid 
• 1345855-04-0 ethyl 5-(4-fluorophenyl )-1-methyl-4-oxo-1,4-dihydropyridine-3-carboxylate 
• 1528549-08-7 C₃₀H₂₆F₂N₄O₅ 
• 1528546-94-2 N-(4-(2,3-dihydro-1H-pyrrolo[2,3-b] pyridin-4-yloxy)-3-fluorophenyl)-5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxamide 
• 1528546-96-4 N-(3-fluoro-4-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-8-yloxy)phenyl)-5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxamide 
• 1449300-94-0 1-[2-(dimethylamino)-2-oxoethyl]-5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid 
• 1449299-70-0 N-{4-[2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-1-(2-fluoroethyl)-5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxamide 
• 1449300-83-7 1-(2-fluoroethyl)-5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid 
• 1449299-66-4 N-{4-[2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-5-(4-fluorophenyl)-1-(2-methoxyethyl)-4-oxo-1,4-dihydropyridine-3-carboxamide 
• 1449300-80-4 5-(4-fluorophenyl)-1-(2-methoxyethyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid 
• 1449300-57-5 N-[4-(6-amino-2'-methyl-3,4'-bipyridin-5-yl)phenyl]-1-(2-fluoroethyl)-5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxamide 
• 1449300-41-7 N-{4-[2-amino-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-3-yl]phenyl}-1-(2-fluoroethyl)-5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxamide 
• 1449301-44-3 tert-butyl 4-(4-[6-amino-5-[4-({[1-(2-fluoroethyl)-5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridin-3-yl]carbonyl}amino)phenyl]pyridin-3-yl]-1H-pyrazol-1-yl)piperidin-1-carboxylate 
• 1449300-22-4 N-[4-(2-amino-5-{4-[(2R)-1,4-dioxan-2-ylmethoxy]-3-methoxyphenyl}pyridin-3-yl)phenyl]-1-(2-fluoroethyl)-5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxamide 

Relevant articles and documents

Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation

Axl has emerged as an attractive target for cancer therapy due to its strong correlation with tumor growth, metastasis, poor survival, and drug resistance. Herein, we report the design, synthesis and structure-activity relationship (SAR) investigation of a series of pyrrolo[2,3-d]pyrimidine derivatives as new Axl inhibitors. Among them, the most promising compound 13b showed high enzymatic and cellular Axl potencies. Furthermore, 13b possessed preferable pharmacokinetic properties and displayed promising therapeutic effect in BaF3/TEL-Axl xenograft tumor model. Compound 13b may serve as a lead compound for new antitumor drug discovery.

Bioisosteric replacement of an acylureido moiety attached to an indolin-2-one scaffold with a malonamido or a 2/4-pyridinoylamido moiety produces a selectively potent Aurora-B inhibitor

Bioisosteric replacement of acylureido moiety in 6-acylureido-3- pyrrolylmethylidene-2-oxoindoline derivatives resulted in a series of malonamido derivatives with indolin-2-one scaffold (11-14). Further conformational restrictions of the malonamido moiety led to 2-oxo-1,2-dihydropyridine (21-25) or a 4-oxo-1,4-dihydropyridine derivatives (31-36). 4-Oxo-1,4-dihydropyridine derivatives were more potent Aurora B inhibitors than their 2-oxo-1,2- dihydropyridine counterparts and demonstrated cytotoxicities against A549 and HepG2 cells in the submicromolar range. In A549 cells, 31h decreased phosphorylation of histone H3, triggered polyploidy, induced expression of pro-apoptotic Fas and FasL with subsequent activation of caspase 8, resulting into apoptosis. In a Huh7-xenograft mouse model, 31h demonstrated potent in vivo efficacy with a daily dose of 5 mg/kg.

PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES

Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. Pharmaceutical compositions and methods of treatment employing the compounds disclosed herein are also disclosed.